Alice announced that the company received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the application for the marketing of vometinib mesylate tablets for adult non-small cell lung cancer patients with EGFR exon 19 deficiency or exon 21 replacement mutations for new indications of adjuvant treatment after tumor resection was accepted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.